Related Experiment Videos
Vinflunine
1Cancer Research Unit, Tom Connors Cancer Research Centre, University of Bradford, Richmond Road, Bradford, BD7 1DP, UK. S.D.Shnyder@Bradford.ac.uk
Idrugs : the Investigational Drugs Journal
|October 8, 2004
Summary
Pierre Fabre SA and Bristol-Myers Squibb Co are developing vinflunine, a novel fluorinated vinca alkaloid, as a promising anticancer therapeutic agent. This compound shows potential for cancer treatment through its unique chemical structure and mechanism of action.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Vinca alkaloids are a class of naturally derived compounds with established anticancer properties.
- There is an ongoing need for novel anticancer agents with improved efficacy and safety profiles.
- Fluorination of existing drug scaffolds can modulate pharmacokinetic and pharmacodynamic properties.
Purpose of the Study:
- To introduce and describe the development of vinflunine, a novel fluorinated vinca alkaloid.
- To highlight its potential as an anticancer agent.
Main Methods:
- Chemical synthesis and characterization of vinflunine.
- Preclinical evaluation of anticancer activity (details not provided in abstract).
Main Results:
- Vinflunine has been successfully developed as a fluorinated vinca alkaloid.
- It is being investigated as a potential anticancer agent.
Conclusions:
- Vinflunine represents a novel therapeutic candidate in the field of oncology.
- Further research and clinical trials are warranted to establish its efficacy and safety in cancer patients.